Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of DN022150 versus investigator's choice chemotherapy in KRAS G12D-mutant advanced pancreatic cancer after prior systemic therapy
CTR20262230Phase 3Active
- Sponsor
- Jiangxi Kerui Pharmaceutical Co., Ltd.
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of DN-022150 in pancreatic cancer (PC) (2 arms), sponsored by Jiangxi Kerui Pharmaceutical Co., Ltd. Primary endpoints: Progression-free survival and Overall survival. Started Aug 2026; status: active.
02
Drugs
DN-022150
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on CTR20262230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262230.